Early rather than deferred androgen-suppression therapy more beneficial for advanced prostate cancer

In men with clinically localised prostate cancer who were either unable or unwilling to undergo local treatment with curative intent, or who had locally advanced prostate cancer, node positive disease and/or (asymptomatic) metastatic disease, this review favoured early over delayed AST. This was reflected in lower risk of dying from prostate cancer or from any cause (moderate-certainty evidence), and in slightly lower risk of problems related to bony metastases (low-certainty evidence). Rates of serious adverse events and quality of life were similar (low-certainty evidence). Early therapy was associated with increased fatigue and risk of heart failure (low-certainty evidence).